Literature DB >> 23899679

Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort.

Mira Hleyhel1, Aurélien Belot, Anne Marie Bouvier, Pierre Tattevin, Jérôme Pacanowski, Philippe Genet, Nathalie De Castro, Jean-Luc Berger, Caroline Dupont, Armelle Lavolé, Christian Pradier, Dominique Salmon, Anne Simon, Valérie Martinez, Dominique Costagliola, Sophie Grabar.   

Abstract

BACKGROUND: We examined trends in the incidence of the 3 AIDS-defining cancers (ADCs; Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cervical cancer) among human immunodeficiency virus (HIV)-infected patients relative to the general population between 1992 and 2009 in France, focusing on age at ADC diagnosis and on patients with controlled viral load and restored immunity on combination antiretroviral therapy (cART).
METHODS: Age- and sex-standardized incidence rates were estimated in patients enrolled in the French hospital database on HIV, and in the general population in France during 4 calendar periods (1992-1996, 1997-2000, 2001-2004, and 2005-2009). Standardized incidence ratios (SIRs) were calculated for all periods and separately for patients on cART, with CD4 counts ≥500 cells/µL for at least 2 years and viral load ≤500 copies/mL.
RESULTS: Although the incidence of ADCs fell significantly across the calendar periods, the risk remained constantly higher in HIV-infected patients than in the general population. In patients with restored immunity, the relative risk remained significantly elevated for KS (SIR = 35.4; 95% confidence interval [CI], 18.3-61.9), and was similar to that of the general population for NHL (SIR = 1.0; 95% CI, .4-1.8). ADCs were diagnosed at a younger age in HIV-infected patients, with a particularly marked difference for NHL (-11.3 years, P < .0001).
CONCLUSIONS: The incidence of all ADCs continued to fall, including cervical cancer, in the cART period, but the risk remained higher than in the general population in 2005-2009. In patients with stably restored immunity, KS remained significantly more frequent than in the general population.

Entities:  

Keywords:  HIV; aging; cancer; restored immunity; risk

Mesh:

Substances:

Year:  2013        PMID: 23899679     DOI: 10.1093/cid/cit497

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

Review 2.  Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era.

Authors:  Cristina Brickman; Joel M Palefsky
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

3.  The influence of antiretroviral therapy on clinical aspects of HIV-related lymphoma.

Authors:  José-Tomás Navarro; Josep-Maria Ribera
Journal:  Int J Hematol Oncol       Date:  2017-11-17

Review 4.  Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era.

Authors:  Cristina Brickman; Joel M Palefsky
Journal:  Curr HIV/AIDS Rep       Date:  2015-12       Impact factor: 5.071

5.  Cutaneous manifestations of human immunodeficiency virus: a clinical update.

Authors:  Kirstin Altman; Erin Vanness; Ryan P Westergaard
Journal:  Curr Infect Dis Rep       Date:  2015-03       Impact factor: 3.725

6.  Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.

Authors:  Adriana Weinberg; Sharon Huang; Anna-Barbara Moscicki; Afred Saah; Myron J Levin
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.177

Review 7.  Evolving epidemiology of HIV-associated malignancies.

Authors:  Meredith S Shiels; Eric A Engels
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

8.  Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.

Authors:  Michael J Silverberg; Bryan Lau; Chad J Achenbach; Yuezhou Jing; Keri N Althoff; Gypsyamber D'Souza; Eric A Engels; Nancy A Hessol; John T Brooks; Ann N Burchell; M John Gill; James J Goedert; Robert Hogg; Michael A Horberg; Gregory D Kirk; Mari M Kitahata; Philip T Korthuis; William C Mathews; Angel Mayor; Sharada P Modur; Sonia Napravnik; Richard M Novak; Pragna Patel; Anita R Rachlis; Timothy R Sterling; James H Willig; Amy C Justice; Richard D Moore; Robert Dubrow
Journal:  Ann Intern Med       Date:  2015-10-06       Impact factor: 25.391

9.  Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.

Authors:  Virginia A Carroll; Mark K Lafferty; Luigi Marchionni; Joseph L Bryant; Robert C Gallo; Alfredo Garzino-Demo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

10.  Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012.

Authors:  Lesley S Park; Janet P Tate; Keith Sigel; David Rimland; Kristina Crothers; Cynthia Gibert; Maria C Rodriguez-Barradas; Matthew Bidwell Goetz; Roger J Bedimo; Sheldon T Brown; Amy C Justice; Robert Dubrow
Journal:  AIDS       Date:  2016-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.